Historical Valuation
IDEAYA Biosciences Inc (IDYA) is now in the Overvalued zone, suggesting that its current forward PS ratio of 124.28 is considered Overvalued compared with the five-year average of -11.43. The fair price of IDEAYA Biosciences Inc (IDYA) is between 15.79 to 35.71 according to relative valuation methord. Compared to the current price of 37.18 USD , IDEAYA Biosciences Inc is Overvalued By 4.11%.
Relative Value
Fair Zone
15.79-35.71
Current Price：37.18
4.11%
Overvalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
IDEAYA Biosciences Inc (IDYA) has a current Price-to-Book (P/B) ratio of 2.72. Compared to its 3-year average P/B ratio of 2.72 , the current P/B ratio is approximately -0.28% higher. Relative to its 5-year average P/B ratio of 2.59, the current P/B ratio is about 4.79% higher. IDEAYA Biosciences Inc (IDYA) has a Forward Free Cash Flow (FCF) yield of approximately -3.55%. Compared to its 3-year average FCF yield of -8.12%, the current FCF yield is approximately -56.24% lower. Relative to its 5-year average FCF yield of -6.64% , the current FCF yield is about -46.52% lower.
P/B
Median3y
2.72
Median5y
2.59
FCF Yield
Median3y
-8.12
Median5y
-6.64
Competitors Valuation Multiple
AI Analysis for IDYA
The average P/S ratio for IDYA competitors is 33.58, providing a benchmark for relative valuation. IDEAYA Biosciences Inc Corp (IDYA.O) exhibits a P/S ratio of 124.28, which is 270.07% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for IDYA
1Y
3Y
5Y
Market capitalization of IDYA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of IDYA in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is IDYA currently overvalued or undervalued?
IDEAYA Biosciences Inc (IDYA) is now in the Overvalued zone, suggesting that its current forward PS ratio of 124.28 is considered Overvalued compared with the five-year average of -11.43. The fair price of IDEAYA Biosciences Inc (IDYA) is between 15.79 to 35.71 according to relative valuation methord. Compared to the current price of 37.18 USD , IDEAYA Biosciences Inc is Overvalued By 4.11% .
What is IDEAYA Biosciences Inc (IDYA) fair value?
IDYA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of IDEAYA Biosciences Inc (IDYA) is between 15.79 to 35.71 according to relative valuation methord.
How does IDYA's valuation metrics compare to the industry average?
The average P/S ratio for IDYA's competitors is 33.58, providing a benchmark for relative valuation. IDEAYA Biosciences Inc Corp (IDYA) exhibits a P/S ratio of 124.28, which is 270.07% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for IDEAYA Biosciences Inc (IDYA) as of Jan 09 2026?
As of Jan 09 2026, IDEAYA Biosciences Inc (IDYA) has a P/B ratio of 2.72. This indicates that the market values IDYA at 2.72 times its book value.
What is the current FCF Yield for IDEAYA Biosciences Inc (IDYA) as of Jan 09 2026?
As of Jan 09 2026, IDEAYA Biosciences Inc (IDYA) has a FCF Yield of -3.55%. This means that for every dollar of IDEAYA Biosciences Inc’s market capitalization, the company generates -3.55 cents in free cash flow.
What is the current Forward P/E ratio for IDEAYA Biosciences Inc (IDYA) as of Jan 09 2026?
As of Jan 09 2026, IDEAYA Biosciences Inc (IDYA) has a Forward P/E ratio of -9.02. This means the market is willing to pay $-9.02 for every dollar of IDEAYA Biosciences Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for IDEAYA Biosciences Inc (IDYA) as of Jan 09 2026?
As of Jan 09 2026, IDEAYA Biosciences Inc (IDYA) has a Forward P/S ratio of 124.28. This means the market is valuing IDYA at $124.28 for every dollar of expected revenue over the next 12 months.